11th April 2019

BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference

 

Bergen, Norway, April 09 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers, announces that Richard Godfrey, BerGenBio’s Chief Executive Officer, will present an overview of the Company at the H.C. Wainwright Global Life Sciences Conference today, April 9, 2019.

 

Date:              Tuesday, April 9, 2019

Time:             09:10 AM BST

Location:        JW Marriott Grosvenor House, London, UK

 

The presentation slides will be available on www.bergenbio.com in the investor section at time of presentation.

- END -

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focussed on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing Phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

 

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

 

Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com

+47 917 86 513

International Media Relations

 

Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Carina Jurs, Consilium Strategic Communications bergenbio@consilium-comms.com

+44 20 3709 5700

Media Relations in Norway

 

Jan Petter Stiff, Crux Advisers stiff@crux.no

+47 995 13 891

Forward looking statements

 

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

 


Back to previous page